Abstract
Purpose: To evaluate the association between the biological disease-modifying anti-rheumatic drugs (bio-DMARDs) and the incidence of diabetes. Methods: Studies recording the incidence of new-onset diabetes in subjects treated with bio-DMARDs were included. Results: In total, 23 relevant studies were included. The pooled analysis suggested that bio-DMARDs treatment did not reduce the incidence of diabetes (RR= 0.87, 95% CI, 0.69 to 1.08, P = 0. 21) compared with non-bioDMARDs. However, subgroup analyses revealed incidence of new-onset diabetes was significantly reduced in patients with abatacept treatment (RR = 0.61, 95% CI, 0.38 to 0.99, P = 0.04). Conclusions: The utilization of bio-DMARDs in general was not associated with the incidence of diabetes while the abatacept treatment may reduce the risk of diabetes. Disclosure C. Lin: None. H. Ji: None. X. Cai: None. W. Yang: None. L. Ji: None. Funding National Natural Science Foundation of China (81970698); National Key Research and Development Program of China (2016YFC1304901)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
